EFFECTIVE USE OF VISCOSUPPLEMENTATION AFTER KNEE ARTHROSCOPY: EXPERIENCE FROM A WORKING GROUP

Christian Fuentes1, Paulo J. Llinas2, Allan W. Chew3, Fabricio Ponce4, José G. Ibarra5 and Carlos Gavín6

1. Hospital Arco Iris, La Paz, Bolivia.
2. Fundación Arco Iris, La Paz, Bolivia.
3. Hospital Roosevelt, Guatemala City, Guatemala.
4. Hospital Clínica San Francisco, Guayaquil, Ecuador.
5. Centro Médico Hidalgo, Monterrey, Nuevo León, Mexico.
6. Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.

Manuscript Info

Abstract

The aim of this work was to assess the efficacy of viscosupplementation after knee arthroscopy in a series of cases and to propose an adequate dosage regimen. The cases studied corresponded to patients undergoing arthroscopic surgery presenting meniscal injury and/or free bodies and where osteoarthritis could be present. Viscosupplementation started 3 weeks after arthroscopy and one set of patients received one shot of 5 ml of hyaluronic acid and the other set received three injections of 2.5 ml with weekly intervals. Patients were followed at 3 and 6 months. Improvements in pain and function as well as patient satisfaction were assessed and the appearance of adverse events was monitored. The groups studied were homogeneous with no differences in the type of surgery, associated gestures or other procedures performed during the intervention. Considering the patients as a whole, significant improvements were observed at 3 weeks post-arthroscopy (prior to intra-articular treatment) and at 3 and 6 months compared to pre-arthroscopy scores. Pain reductions were of 39.8%, 63.4% and 80.9% respectively and function improvement was of 20.9%, 58.8% and 77.9% respectively. There were no differences between the two groups in any of the parameters analysed. The treatment was rated by the patients as excellent. The group concluded that viscosupplementation in post-arthroscopy achieves significant pain reduction and function improvement; moreover, one shot of hyaluronic acid is a safe and effective option as an adjuvant treatment in arthroscopic surgery, favouring a better recovery with a lower cost for both the patient and the Healthcare System.

Corresponding Author: Carlos Gavín
Address: Traumatology Department. Hospital Universitario Fundación Alcorcón, C/ Budapest, 1, 28922 Alcorcón, Madrid, Spain.

Copy Right, IJAR, 2021. All rights reserved.
eliminated through lavage. It also allows debridement, whereby joint surfaces and osteophytes can be surgically smoothed out.

Knee osteoarthritis (KOA) is a degenerative disease presenting pain, rigidity and reduction of the joint function. It has a multidisciplinary treatment approach that includes non-pharmacological measures, pharmacological treatments and, ultimately, surgery.

The objective of arthroscopic surgery is to reduce synovitis and eliminate mechanical interference with movement of the joint (Kirkley et al., 2008). Although arthroscopic surgery has been used extensively as treatment in KOA, its use is still controversial. Uncontrolled studies in patients with KOA (Felson and Buckwalter, 2002; Mclaren et al., 1991; Ogilvie-Harris and Fitisialos, 1991; Yang and Nisonson, 1995) described the efficacy of arthroscopic surgery in at least 65% of the patients. However, other controlled and randomised trials (Kirkley et al., 2008; Moseley et al., 2002). have questioned the usefulness of arthroscopy as a treatment for KOA to the point that some scientific associations considered these trials to be a reference for advising against arthroscopic surgery with lavage and/or debridement in patients with primary symptomatic KOA (Jevsevaar, 2013). The available information concludes that arthroscopic surgery is not a treatment of choice in patients with primary KOA alone. However, it must be taken into account that over 90% of patients with symptomatic KOA have a magnetic resonance image (MRI) compatible with meniscal pathology (Bhattacharyya et al., 2003). Therefore, arthroscopic surgery would be indicated in those patients with meniscal or mechanical symptoms presenting a concomitant diagnosis of KOA, and the suitable choice of patients that can benefit from this technique plays an important role (Karpinski et al., 2019).

Viscosupplementation with hyaluronic acid (HA) has been used successfully over the past 2 decades for the treatment of KOA and other joints in patients who do not suitably respond to non-pharmacological, conservative treatments or to simple analgesics, such as paracetamol (Zhang et al., 2008). Its efficacy is supported by a number of clinical trials, post-authorisation studies and various meta-analyses (Waddell and Bert, 2010; Maheu et al., 2019).

Viscosupplementation has also been used as an alternative treatment to delay arthroscopic surgery (Delbarre et al., 2017; Altman et al., 2015; Maheu et al., 2019). In other cases, it has been used to lubricate the joint and as replacement for synovial fluid lost during the intervention. Lastly, the administration of HA after arthroscopic surgery has also been used and has yielded good results because of its analgesic effect, since pain may persist after the intervention (Huskin et al., 2008; Waddell and Bert, 2010).

The published clinical trials (Mathies, 2006; Hempfling, 2007; Thein et al., 2010; Uluçay et al., 2007; Huskin et al., 2008; Atay et al., 2008; Heybeli et al., 2008; Westrich et al., 2009; Chau et al., 2010; Hamawandi, 2021) studying the efficacy of arthroscopic surgery associated with the administration of HA, conclude that combined treatment is effective, relieves post-surgical pain and aids in a faster recovery. However, there is still no consensus as to the administration regimen for HA. The present paper summarises the findings of the evaluation of a case series of patients treated by a working group of specialists in Orthopaedics in the context of their regular clinical practice. The objective was to explore different dose regimens of HA as an adjuvant therapy to alleviate pain after arthroscopic surgery and to reach conclusions that could be of use for the scientific community.

Materials And Methods:
This was a prospective observational evaluation of a case series of patients treated by specialists in Orthopaedics from several Latin American countries and from Spain, in the context of their regular clinical practice and conducted in accordance with the principles of Good Clinical Practice.

The study population included adult subjects with an indication of arthroscopic surgery of the knee presenting meniscal injury and/or the presence of free bodies and where OA could be present. Patients could not be selected if they had a body mass index >35 kg/m², varus-valgus malalignment above 5° with respect to physiological valgus, unstable knee, associated mosaiplasty, chondrocyte grafting, scaffolding or Platelet Rich Plasma (PRP), or meniscal suture or transplant. Type of surgery, surgical manoeuvres and procedures on the cartilage were recorded, as well as the extension and Outerbridge grade of chondral injuries in the tibia, patella and femur.

Three weeks after arthroscopic surgery, patients were randomly allocated to receive one single intra-articular injection of 5 ml of HA (Group 1) or three intra-articular injections of 2.5 ml of HA each with weekly intervals (Group 2). The same HA product was used in all patients: a formulation of sodium hyaluronate obtained by fermentation, with an
intermediate molecular weight (average 900 kDa), and a concentration of 10 mg/ml presented in prefilled syringes. Follow-up visits were performed at 3 and 6 months after treatment by the same physician who administered the treatment. The efficacy of the treatment was assessed as reduction in pain and improvement in function using a 0-100 mm Visual Analogue Scale (VAS) (the higher the score, the worse the condition) at 3 and 6 months post-treatment vs. post-arthroscopy values. Patient satisfaction was also recorded. From a safety point of view, the occurrence of adverse events was monitored.

A sample size of 75 patients was considered sufficient to achieve the objectives of the study. The main population for analysis was the Intention to treat (ITT), composed of those patients that received at least one dose of HA and had at least one evaluation post-treatment. The following descriptive statistics was used: mean and standard deviation plus range for quantitative variables and percentages for qualitative variables. The Kolmogorov-Smirnoff test was performed to show data normality. For comparative statistics, the t-test was used for comparisons of means for independent groups and the paired t-test was used for comparisons of means for dependent or paired groups. For non-normally distributed variables the Student’s t-test for independent samples or the Mann-Whitney test were used. Chi² test or Fisher's exact test were used for comparison of proportions. A logistic regression analysis was performed using the pain reduction or function improvement variables at 3 and 6 months as a dependent variable, with changes of 10, 20 or 30 mm or 10, 20 and 30 %.

The data were analysed using SPSS V14 (SPSS Inc, Chicago Il) and the statistical significance was set at 0.05.

Results:–
The ITT population was composed of 75 patients that received at least one dose of HA and had at least one evaluation post-treatment. The distribution of patients is shown in Figure 1.

The groups were homogeneous in terms of demographic characteristics, comorbidities and pathology at the baseline that are shown in Table 1. The white race was the most common (60.0%), women represent 56 % of the sample and the mean age was 50.2 years.

Previous treatments that were more frequently prescribed for KOA were NSAIDs (50.7%) and physiotherapy (36.2%) with no differences between groups. There were no differences in the type of surgery, associated gestures or other procedures performed during the intervention (Table 2). Partial medial meniscectomy was the most common intervention followed by partial lateral meniscectomy or both. Debridement was the most common associated surgical manoeuvre recorded, followed by abrasion and microfracture. There were also no differences between the groups with respect to the location, extension and Outerbridge grade of the femoral, tibial or patellar injuries.

Compared to pre-arthroscopy values, statistically significant improvements (p<0.001) were found at 3 weeks (prior to intra-articular treatment) and at 3 and 6 months with pain reductions of 37.8%, 64.7% and 77.6% in Group 1; and 41.2%, 62.5% and 83.4% respectively in Group 2. Similarly, improvements found in function were of 17.13%, 68.2% and 80.5% in Group 1 and 23.5%, 52.2% and 77.3% respectively in Group 2 (Figure 2a and 2b). When pain and function values at 3 and 6 months were compared with the values at 3 weeks post-arthroscopy, the improvement observed was statistically significant in both groups (p≤0.001). Nevertheless, there were no differences between the groups in any of the parameters analysed. The patients rated the treatment as excellent.

On an exploratory basis, efficacy was analysed in terms of percentage of patients (responders) presenting an absolute reduction (10 mm, 20 mm, 30 mm) and/or relative reduction (10%, 20%, 30%) of pain and function at follow-up with respect to pre-arthroscopy and 3 weeks post-arthroscopy values. The results showed that there were no statistically significant differences between both treatment groups in the percentage of responders for any of the absolute or relative reduction cut-off points.

A total of 50.7% of the patients used NSAIDs when they entered the study (pre-arthroscopy). With the data obtained at 3 and 6 months, it was observed that the use of NSAIDs (including paracetamol) dropped throughout follow-up in both treatment groups.

No adverse events were recorded during the study nor were any comments related to the safety of the treatments administered.
Discussion:-
Arthroscopic surgery is a commonly applied technique in traumatology, and the knee joint is where this technique is most commonly used. Although arthroscopy per se is not currently considered a treatment of choice for OA, the majority of patients with symptomatic KOA have evidence of meniscal and/or articular surface pathology (Waddell and Bert, 2010), and over 90% of patients with KOA have an MRI compatible with meniscal tears (Bhattacharyya et al, 2003). As such, arthroscopic surgery would be indicated in those patients with meniscal or mechanical symptoms presenting a concomitant diagnosis of KOA. In this sense, recently the American Academy of Orthopaedic Surgeons (AAOS) recommended the use of arthroscopic partial meniscectomy for the treatment of meniscal tears in patients with concomitant mild to moderate OA who have failed physical therapy or other nonsurgical treatments (American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee, Clinical Practice Guideline, 2021).

During arthroscopy, irrigation fluid helps to remove the debris, but it can contribute to the loss of synovial fluid of the joint; with this loss, the concentration of HA decreases, having a negative impact on the metabolism and structure of the joint cartilage (Bulstra et al, 1994; Cuellar et al, 2016; Kohlhof et al, 2016; Bigoni et al, 2017). On the other hand, after knee arthroscopy patients experience pain and function impairment and it has been described that the analgesics used to control pain can result in adverse events (Talu et al, 2002; Gonzales et al, 2016).

Published clinical trials administered viscosupplementation in both immediate and late post-surgery (Shen et al, 2018). Therefore, there is no consensus as to when viscosupplementation should be used or about the dose regimen, although it should be noted that the most recent trials opted administering viscosupplementation at 2-3 weeks post-arthroscopy or even later (Trueba-Vasavilbaso et al, 2017; Hamawandi et al, 2021; Başar et al, 2021; Saw et al, 2021). At 2-3 weeks after arthroscopy, the exudation caused by the surgical procedure stops (Yang et al, 2021); at this time, the administration of HA in the operated joint contributes to pain relief with long lasting effects. HA also improves biological function of synovial membrane and prevents further destruction and disappearance of the cartilage matrix (Yang et al, 2021). The posology of HA to be followed is also a matter of discussion.

Previous published data confirmed the efficacy of this HA product when used in multiple injections after arthroscopic surgery (Trueba-Vasavilbaso et al, 2017). The present study was conducted to explore the possibility of using single injection HA compared to multiple injections to simplify the procedure but maintaining therapeutic efficacy. One group received three injections (2.5 ml each) at weekly intervals while the other was tested with one shot regime (5 ml). In both groups, the treatment started at 3 weeks post-surgery.

Both groups were homogeneous with respect to demographics and baseline characteristics, and there were no differences concerning the type of surgery, associated surgical manoeuvres or other procedures performed during the intervention. Partial medial meniscectomy was the most common intervention followed by partial lateral meniscectomy or both. Debridement was the most common associated surgical manoeuvre recorded, followed by abrasion and microfracture. There were also no differences between the groups with respect to the location, extension and Outerbridge grade of the femoral, tibial or patellar injuries.

The efficacy results in both groups at follow-up in terms of pain reduction and joint functionality showed significant improvements at 3 weeks, and 6 months post-treatment vs. pre-arthroscopy values. It is important to note that the improvements in pain and function at 3 and 6 months increased and were statistically significant and better compared to those at 3 weeks after arthroscopy (before intra-articular treatment), thus confirming the efficacy of the HA treatments administered although there were no differences between groups. The degree of patient satisfaction at 6 months post-treatment was very high and with no differences between groups.

The 50.7% of the patients used NSAIDs when they entered the study (pre-arthroscopy). With the data obtained at 3 and 6 months, it was observed that the use of NSAIDs (including paracetamol) dropped throughout follow-up in both treatment groups. No statistically significant differences with respect to the use of concomitant medication at 3 and 6 months was detected between groups.

On an exploratory basis, efficacy was analysed using different cut-offs in terms of percentage of patients (responders) presenting absolute and/or relative improvement of pain and function with respect to both pre-arthroscopy and 3 weeks post-arthroscopy values. No statistically significant differences were detected at any of the cut-offs used.
The limitations of this study include that both researchers and patients were not kept blind due to the different number of injections on each group and a potential bias in the results could not be disregarded. The use of rescue medication might affect the accuracy of the clinical improvement although a logistic regression analysis performed indicated that the use of concomitant medication had no influence on the assessment of the efficacy of HA treatments. Only VAS for efficacy evaluation was used, with the intention of reproducing the real clinical practice as much as possible, although it would have been interesting to use a more complex index like WOMAC. The study did not use a control group with placebo or surgery alone; however, the superiority of HA over placebo has been recognised (Miller et al., 2013; Bannuru et al., 2015; Trojan et al., 2016). With reference to the presence of a non-treated arm, we compared our results with those of published studies that included a “surgery-alone” group and used similar efficacy variables (Heybeli et al., 2008, Katz and Losina, 2013) to ours; the improvement rates in our study are significantly higher than those obtained in the mentioned control groups suggesting that efficacy rates using HA after arthroscopy are higher than arthroscopy alone.

As regards the safety of HA, no adverse events were recorded while the study was being performed nor were there any comments affecting the safety of the treatments reported, suggesting that both dosage regimens have similar safety profiles.

The meta-analyses published confirmed the efficacy of the combination arthroscopy plus viscosupplementation regardless of the time of administration or the volume of HA administered (Shen et al., 2018; Yang et al., 2021) and it can be considered that there is sufficient data to affirm that HA can be used in both immediate and late post-surgery with good results in terms of pain relief and improvement of joint function. Protocols have been proposed for the use of HA in patients after arthroscopy (Waddell and Bert, 2010). These protocols are mainly based on the analysis of intraoperative findings: presence of OA, Outerbridge grade, etc., which may make viscosupplementation advisable either immediately after-surgery or leaving the joint at rest and waiting 2-3 weeks for administration if pain has not subsided. In our study, the viscosupplementation in late post-arthroscopy achieved a significant reduction of pain and improvement in function with no differences between the dosage regimens studied. In our experience, reducing pain in the postoperative period improves adherence to rehabilitation and, in the long run, the use of NSAIDs is reduced in addition to avoiding chronic pain due to OA. One shot with HA could be considered a safe and effective option as an adjuvant treatment in arthroscopic surgery, favouring a better recovery with a lower cost for both the patient and the Healthcare System, although further controlled trials should be of interest.

Acknowledgements:-
The authors would like to thank to Dr Juan J. Granizo (Granadatos S.L.) for the statistical analysis of the results.

ArthroscopyWorkingGroup
JA Arbeláez, CIRC 3 # 74-37, Medellín, Antioquia, Colombia; A Chew, Hospital Roosevelt, Guatemala City, Guatemala; VR Espinola, IPS Central Santísimo Sacramento, Asunción, Paraguay; C Fuentes, Hospital Arco Iris, La Paz, Bolivia; C Gavín, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain; J Hinzpeter, Hospital Clínico Universidad de Chile, Santiago, Chile; G Ibarra, Centro Médico Hidalgo, Monterrey, Nuevo León, Mexico; PJ Llinas, Fundación Valle de Lili, Cali, Colombia; F Luzuriaga, OMNI Hospital, Guayaquil, Ecuador; L Montiel, Sanatorio Metropolitano, Asunción, Paraguay; JE Navia†, Univ. Del Valle, Calí, Colombia; F Ponce, Hospital Clínica San Francisco, Guayaquil, Ecuador; C Rocha, Fundación Cardioinfantil, Bogotá, Colombia; J Sarango, CEMDER, Miraflores, Lima, Peru; H Valencia, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain; R Vega, Av del Pinar 110/ofc 607, Santiago de Surcos, Lima, Peru.
Figure 1: Distribution of patients.

Table 1: Demographic and baseline characteristics.

|                              | Group 1 N=31 | Group 2 N=44 | Total N=75 |
|------------------------------|--------------|--------------|------------|
| Age, mean (SD)               | 54.13 (16.8) | 47.50 (12.5) | 50.24 (14.7) |
| Gender (female), N (%)       | 21 (67.7)    | 21 (47.7)    | 42 (56.0)  |
| Race, N (%)                  |              |              |            |
| White                        | 18 (58.1)    | 27 (61.4)    | 45 (60.0)  |
| Mestizo                      | 11 (35.5)    | 14 (31.8)    | 25 (33.4)  |
| Black                        | 0 (0.0)      | 1 (2.3)      | 1 (1.3)    |
| Missing                      | 2 (6.5)      | 2 (4.5)      | 4 (5.3)    |
| Clinical history, N (%)      |              |              |            |
| None                         | 21 (67.7)    | 36 (81.8)    | 57 (76.0)  |
| Allergy                      | 1 (3.2)      | 0            | 1 (1.3)    |
| Cardiopathy                  | 0            | 1 (2.8)      | 1 (1.3)    |
| Arterial hypertension (AHT)  | 6 (19.4)     | 3 (6.8)      | 9 (12.0)   |
| Diabetes                     | 2 (6.5)      | 0            | 2 (2.7)    |
| Dyslipemia                   | 3 (9.7)      | 1 (2.3)      | 4 (5.3)    |
| Hypothyroidism               | 2 (6.5)      | 1 (2.3)      | 3 (4.0)    |
| Findings N (%)               |              |              |            |
| Osteoarthritis               | 5 (16.1)     | 13 (29.5)    | 18 (24)    |
| Pain                         | 19 (61.3)    | 21 (47.8)    | 40 (53.4)  |
| Variable                                | Group 1 | Group 2 | Total | p     |
|-----------------------------------------|---------|---------|-------|-------|
| **Pain at baseline (VAS, mm) (Mean, SD)**|         |         |       |       |
| Stiffness                               | 2 (6.5) | 6 (13.6) | 8 (10.7) |       |
| Meniscal syndrome                       | 11 (35.5) | 13 (29.5) | 24 (32.0) |       |
| Others                                  | 6 (19.4) | 3 (6.8) | 9 (12.0) |       |
| **Function at baseline (VAS, mm) (Mean, SD)** |         |         |       |       |
| Pain at baseline (VAS, mm) (Mean, SD)   | 71.8 (16.6) | 66.0 (19.6) | 68.4 (18.5) |       |
| Function at baseline (VAS, mm) (Mean, SD) | 60.4 (21.6) | 60.6 (21.5) | 60.5 (21.4) |       |

Table 2: Surgery.

| Variable                                | Group 1 | Group 2 | Total | p     |
|-----------------------------------------|---------|---------|-------|-------|
| **Type of surgery N (%)**               |         |         |       |       |
| Partial lateral meniscectomy            | 5 (16.2) | 10 (22.7) | 15 (20.0) | 0.481 |
| Partial medial                          | 20 (64.5) | 20 (45.5) | 40 (53.3) | 0.103 |
| Partial medial + partial lateral        | 3 (9.7) | 4 (9.1) | 7 (9.3) | 1.000 |
| Lateral subtotal                        | 0       | 3 (6.8) | 3 (4.0) | 0.262 |
| Partial medial and subtotal             | 0       | 1 (2.3) | 1 (1.3) | 1.000 |
| Medial subtotal                         | 0       | 1 (2.3) | 1 (1.3) | 1.000 |
| Not described                           | 3 (9.7) | 6 (13.6) | 9 (12.0) | 0.728 |
| **Associated surgical procedure N (%)** |         |         |       |       |
| Debridement                             | 23 (74.2) | 32 (72.7) | 55 (73.3) | 0.888 |
| Abrasion                                | 5 (16.1) | 15 (34.1) | 20 (26.7) | 0.083 |
| Microfracture                           | 5 (16.1) | 7 (15.9) | 12 (16.0) | 1.000 |
| Perforation                             | 1 (3.2) | 2 (4.5) | 3 (4.0) | 1.000 |
| **Other procedures N (%)**              |         |         |       |       |
| Synovecctomy                            | 13 (41.9) | 21 (47.7) | 34 (45.3) | 0.620 |
| Suture                                  | 0       | 1 (2.3) | 1 (1.3) | 1.000 |
| ACL tightening                          | 2 (6.5) | 2 (4.5) | 4 (5.3) | 1.000 |
| Realignment                             | 0       | 1 (2.3) | 1 (1.3) | 1.000 |
| Plica                                   | 3 (9.7) | 1 (2.3) | 4 (5.3) | 0.300 |
| Removal of foreign body                 | 7 (22.6) | 12 (27.3) | 19 (25.3) | 0.645 |

Figure 2: Comparison of the differences in a) pain and b) function along the study vs baseline.
Pre-A: pre-arthroscopy; PA: post-arthroscopy; PI: post-injection
P<0.001: *Group1; # Group 2 vs Pre-A

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure
The results of this study were partially presented as a poster at the 2019 Congress of Pan American League of Associations for Rheumatology (PANLAR).

Conflicts Of Interest
The authors declare that they have no conflicts of interest regarding the publication of this paper.

References:
1. Altman R, Lim S, Steen RG, Dasa V (2015). Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. PLoS One. 22;10(12):e0145776.
2. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline. https://www.aaos.org/oak3cpg Published 08/31/2021.
3. Atay T, Aslan A, Baydar ML, Ceylan B, Baykal B, Kirdemir V (2008). The efficacy of low- and high-molecular–weight hyaluronic acid applications after arthroscopic debridement in patients with osteoarthritis of the knee. Acta Orthop Traumatol Turc. 42(4):228-33.
4. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE (2015). Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 162(1):46-54.
5. Başar B, Başar G, Büyükkuşçu MÖ, Başar H (2021). Comparison of physical therapy and arthroscopic partial meniscectomy treatments in degenerative meniscus tears and the effect of combined hyaluronic acid injection with these treatments: A randomized clinical trial. J Back Musculoskelet Rehabil. 34(5):767-74.
6. Bhattacharyya T, Gale D, Dewire P, Totterman S, Gale ME, McLaughlin S, Einhorn TA, Felson DT (2003). The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. J Bone Joint Surg Am. 85(1):4-9.
7. Bigoni M, Turati M, Sacerdote P, Gaddi D, Piatti M, Castelnuovo A, Franchi S, Gandolla M, Pedrocchi A, Omeljaniuk RJ, Besciani E, Locatelli V, Torsello A (2017). Characterization of synovial fluid cytokine profiles in chronic meniscal tear of the knee. J Orthop Res. 35:340–46.
8. Bulstra SK, Kuijer R, Eerdmans P, van der Linden AJ (1994). The effect in vitro of irrigating solutions on intact rat articular cartilage. J Bone Joint Surg Br. 76:468–70.
9. Chau JY, Chan WL, Woo SB, Cheng SC, Wong TM, Wong TK, Yen CH, Wong K, Wong WC (2012). Hyaluronic acid instillation following arthroscopic anterior cruciate ligament reconstruction: a double-blinded, randomised controlled study. J Orthopaedic. 20(2):162-5.
10. Cuellar VG, Cuellar JM, Kirsch T, Strauss EJ (2016). Correlation of synovial fluid biomarkers with cartilage pathology and associated outcomes in knee arthroscopy. Arthroscopy. 32:475–85.
11. Delbarre A, Amor B, Bardoulat I, Tetafort A, Pelletier-Fleury N (2017). Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis - A Cox model analysis. PLoS One. 12(11):e0187227.
12. Felson DT, Buckwalter J (2002). Debridement and lavage for osteoarthritis of the knee. N Engl J Med. 347:132-3.
13. Gonzales J, Lovald ST, Lau EC, Ong KL (2016). Quantifying the risk of analgesic-related adverse events after knee arthroscopy. J Surg Orthop Adv. 25:215–221.
14. Hamawandi SA. Use of hyaluronic acid injection after arthroscopic release in lateral patellar compression syndrome with degenerative cartilage changes: randomized control trial (2021). BMC Musculoskeletal Disorders. 22(1):1–8.
15. Hempfling H (2007). Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. Knee Surg Sports Traumatol Arthrosc. 15:537-46.
16. Heybeli N, Doral MN, Atay OA, Leblebicioglu G, Uzümcügil A (2008). Intra-articular sodium hyaluronate injections after arthroscopic debridement for osteoarthritis of the knee: a prospective, randomized, controlled study. Acta Orthop Traumatol Turc. 42(4):221-7.
17. Huskin JP, Vandezereckhove B, Delincé P, Verdonck R, Dubuc JE, Willems S, Hardy P, Blanco FJ, Charrois O, Handelberg F (2008). Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy. Knee Surg Sports Traumatol Arthrosc. 16:747-52.
18. Jevsevar DS (2013). Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg; 21(9):571-6.
19. Karpinski K, Müller-Rath R, Niemeyer P, Angele P, Petersen W (2019). Subgroups of patients with osteoarthritis and medial meniscus tear or crystal arthropathy benefit from arthroscopic treatment. Knee Surg Sports Traumatol Arthrosc. 27(3):782-796.
20. Katz JN, Losina E (2013). Surgery versus physical therapy for meniscal tear and osteoarthritis. N Engl J Med. 369(7): 677-8.
21. Kirkley A, Birmingham TB, Litchfield RB, Giffin JR, Willits KR, Wong CJ, Feagan BG, Donner A, Griffin SH, D’Ascanio LM, Pope JE, Fowler PJ (2008). A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 359(11):1097-107.
22. Kohlhof H, Gravius S, Kohl S, Ahmad SS, Randau T, Schmolders J, Rommelspacher Y, Friedrich M, Kaminiski TP (2016). Single molecule microscopy reveals an increased hyaluronan diffusion rate in synovial fluid from knees affected by osteoarthritis. Sci Rep. 2016 Feb 12; 6:21616.
23. Maheu E, Bannuru RR, Herrero-Beaumont G, Allali F, Bard H, Migliore A (2019). Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. Semin Arthritis Rheum. 48(4):563-572.
24. Mathies B (2006). Effects of Viscoseal, a synovial fluid substitute, on recovery after arthroscopic partial meniscectomy and joint lavage. Knee Surg Sports Traumatol Arthrosc. 14:32-9.
25. Mclaren AC, Blokker CP, Fowler PJ, Roth JN, Rock MG (1991). Arthroscopic debridement of the knee for osteoarthritis. Can J Surg. 34(6): 595-8.
26. Miller LE, Block JE (2013). US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials. Clin Med Insights Arthritis Musculoskelet Disord. 6:57-63.
27. Moseley JB, O'Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP (2002) A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 347(2): 81-8.
28. Ogilvie-Harris DJ, Fitisios DP (1991). Arthroscopic management of the degenerative knee. Arthroscopy. 7(2): 151-7.
29. Saw KY, Anz AW, Ng RC, Jee CS, Low SF, Dorvagut C, Johnson KB (2021). Arthroscopic Subchondral Drilling Followed by Injection of Peripheral Blood Stem Cells and Hyaluronic Acid Showed Improved Outcome Compared to Hyaluronic Acid and Physiotherapy for Massive Knee Chondral Defects: A Randomized Controlled Trial. Arthroscopy. 37(8):2502-17.
30. Shen D, Chen M, Chen K, Wang T, Lu L, Yang X (2018). Efficacy of hyaluronic acid after knee arthroscopy: A systematic review and meta-analysis. J Rehabil Med. 50(10):860-865.

31. Talu GK, Ozyalçin S, Koštka K, Ertürk E, Akinci O, Aşik M, Pembeşi K (2002). Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery. Knee Surg Sports Traumatol Arthrosoc. 10:355–360.

32. Thein R, Haviv B, Kidron A, Bronak S (2010). Intra-articular injection of hyaluronic acid following arthroscopic partial meniscectomy of the knee. Orthopedics. 33(10):724.

33. Trojan TH, Concoff AL, Joy SM, Hatzenbuehler JR, Saulsberry WJ, Coleman CJ (2016). AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes. Br J Sports Med. 50(2):84-92.

34. Trueba Vasavilbaso C, Rosas Bello CD, Medina López E, Coronel Granado MP, Navarrete Álvarez JM, Trueba Davalillo CA, Gil Orbezo FI (2017). Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement. Open Access Rheumatol. 9:171-179.

35. Uluçay C, Altintaş F, Uğutmen E, Beksaç B (2007). The use of arthroscopic debridement and viscosupplementation in knee osteoarthritis. Acta Orthop Traumatol Turc. 41(5): 337-42.

36. Waddell DD, Bert JM (2010). The use of hyaluronan after arthroscopic surgery of the knee. Arthroscopy. 26 (1): 105-11.

37. Westrich G, Schaefer S, Walcott-Sapp S, Syman S (2009). Randomized prospective evaluation of adjuvant Hyaluronic acid therapy administered after knee arthroscopy. Am J Orthop. 38(12):612-6.

38. Yang SS, Nisonson B (1995). Arthroscopic surgery of the knee in the geriatric patient. Clin Orthop Relat Res. (316):50-8.

39. Yang X, Liang W, Li J, Liu P (2021). A meta-analysis and systematic review of the therapeutic effects of arthroscopy combined with intra-articular injection of sodium hyaluronate in the treatment of knee osteoarthritis. Ann Palliat Med. 10(9):9859-9869.

40. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008). OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 16:137-62.